Sanofi

In 1999, two science-based companies with shared visions came together to form AstraZeneca: Sweden's Astra AB and the UK's Zeneca Group PLC. This strategic merger combined decades of pharmaceutical expertise, creating a global powerhouse uniquely positioned to push the boundaries of scientific discovery. What began as a union of strengths has evolved into a relentless pursuit of breakthrough therapies, with the company investing billions annually in research and development to transform patient outcomes across oncology, biopharmaceuticals, respiratory, and rare diseases. Today, AstraZeneca stands at the forefront of precision medicine and next-generation therapeutics, harnessing the power of data science, AI, and innovative technologies like cell therapies. With 197 projects in the pipeline and 16 blockbuster medicines, the company operates from six strategic R&D centres spanning Cambridge, Gothenburg, Gaithersburg, Boston, Shanghai, and Beijing. Their bold aspiration to deliver 20 new medicines by 2030 reflects an unwavering commitment to following the science and putting patients first - values that have driven every decision since that pivotal merger more than two decades ago.

We're a medicine company that's been turning science into healing for nearly 150 years. Founded in 1876 by Colonel Eli Lilly in Indianapolis, Indiana, we started with a simple mission: create high-quality medicines that meet real needs. Today, our team of about 48,000 people around the world continues that work, combining scientific rigor with genuine care for the patients we serve. We're not just in the business of making medicines - we're committed to growing our business in ways that actually benefit people and society. Every day, we focus on discovering and developing treatments that can make a meaningful difference in people's lives. From diabetes care to obesity treatments and beyond, we work across many therapeutic areas because we know health challenges are complex. But we also know that beyond the science, real impact comes from listening to patients, understanding their needs, and staying true to our founding commitment to quality and integrity. That's what drives us forward.

Founded in 1920, Endo International plc is a specialty pharmaceutical company with global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, Pennsylvania. The company has historically focused on developing, manufacturing, and marketing quality branded and generic pharmaceutical products across key therapeutic areas including pain management, urology, and oncology. Endo's product portfolio includes widely recognized medications such as Percocet, along with numerous generic and branded specialty pharmaceuticals. The company operates through multiple business segments and has grown through strategic acquisitions, including the purchase of American Medical Systems in 2011 and Par Pharmaceutical in 2015. In a significant corporate development, Endo merged with Mallinckrodt Pharmaceuticals on July 31, 2025, creating a combined entity that subsequently divided into two independent companies: Par Health, focusing on generics and sterile injectables, and Keenova Therapeutics, concentrating on specialty therapeutics.

At Agenus, we're driven by a singular, unwavering mission: to end the suffering of cancer patients. For over 30 years, our team of scientists, researchers, and professionals has been united by this purpose, working collaboratively across the US and Europe to discover, develop, and manufacture breakthrough immuno-oncology therapies. Our research and innovation engine has built a comprehensive pipeline of novel immunotherapies that empower the body to recognize and eliminate disease. We believe that the key to transforming cancer treatment lies in harnessing the full power of the immune system - activating it to do what it was meant to do. Our culture is defined by scientific excellence, relentless innovation, and an unwavering focus on patients. We thrive on tackling the toughest challenges in oncology, particularly in areas where current therapies fall short - cold tumors and late-stage cancers that have resisted traditional treatments. The people who thrive here are those who share our passion for making a meaningful difference, who embrace collaboration across disciplines, and who are motivated by the potential to deliver curative therapies to patients who need them most. Every day, we're pushing the boundaries of what's possible in immunotherapy, united by our vision of a future where more patients live longer, fuller lives.

Genentech pioneered the biotechnology industry and revolutionized treatment for some of the most complex health problems. For nearly 50 years, the company has pursued groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Founded in 1976 by venture capitalist Robert A. Swanson and biochemist Dr. Herbert W. Boyer, Genentech has consistently pushed the boundaries of what is possible in biomedical research. The company's transformational discoveries include the first personalized medicine for cancer and the first medicine for primary progressive multiple sclerosis. Today, Genentech operates as a member of the Roche Group, galvanizing the greatest minds across their business to make lasting improvements in healthcare. Their approach includes novel customer engagement strategies, state-of-the-art manufacturing facilities, and integrating AI for molecule discovery. With a $50 billion commitment to U.S. manufacturing and R&D, Genentech remains dedicated to leveling barriers to clinical trial participation, driving inclusive research, and optimizing health outcomes for all patients.

The purpose of Idorsia is to discover, develop, and commercialize innovative medicines to help more patients. We have more ideas, we see more opportunities, and we want to transform the horizon of therapeutic options. Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is a high-potential biopharmaceutical company, specialized in the discovery, development and commercialization of innovative small molecules. Our team is dedicated to bringing innovative medicines from bench to bedside, with operations spanning multiple locations across North America, Europe, and Asia. We conduct research, clinical development, and commercial operations out of these global locations. Idorsia's corporate responsibility efforts encompass employee development and diversity, governance and ethics, as well as the organization's economic, environmental, and social performance.